Flurbiprofen + ChloramphenicolThird Party Manufacturing in India

Flurbiprofen + Chloramphenicol works by simultaneously controlling acute structural inflammation and eradicating bacterial pathogens. It inhibits cyclooxygenase to stop localized prostaglandin generation while binding reversibly to the 50S ribosomal subunit to arrest bacterial protein translation. Unlike monotherapy regimens, it provides comprehensive coverage against post-surgical intraocular inflammatory damage while maintaining a sterile barrier against opportunistic gram-positive and gram-negative microbes. It is highly effective and well-tolerated in postoperative management.

Therapeutic Uses

• Postoperative Ophthalmic Care: Concurrent prevention of post-cataract ocular infection and management of localized structural inflammation.
• Superficial Ocular Infections: Management of painful bacterial conjunctivitis or keratitis accompanied by pronounced tissue swelling.

Why Manufacturers Choose Flurbiprofen + Chloramphenicol

Flurbiprofen + Chloramphenicol third party manufacturing in India satisfies an immediate demand from clinical ophthalmologists for simple, combined postoperative therapies. Our partner production lines carry full WHO-GMP certification, guaranteeing the precise aseptic compounding and uniform distribution of both active ingredients. By choosing these validated WHO-GMP certified environments, distributors can confidently market a product with minimal degradation profiles. This targeted combination simplifies patient compliance, driving repeat procurement from corporate hospital chains.